CD27+ IgM- IgD- Test

If you have struggled with frequent infections, sinus or lung trouble that keeps coming back, or unexplained low antibody levels, this measurement gets at a question your standard labs cannot answer: are the cells that actually mature into antibody factories present in your blood, or are they missing?

This subset, called CSM (class-switched memory) B cells, reflects whether your immune system has completed the training process that produces durable, high-quality IgG and IgA antibodies. When this number is low, your body may look fine on a basic immune panel while quietly lacking the cells that drive long-term protection.

What This Cell Population Actually Reflects

CSM cells are B cells that carry the surface marker CD27 and have lost their original IgM and IgD antibody coats. The shedding of those two antibody types means the cell has gone through class-switch recombination, the process that lets your immune system produce IgG, IgA, and IgE antibodies instead of just the early-response IgM.

These cells are made in the germinal centers, training camps inside lymph nodes and the spleen where B cells learn to make highly specific antibodies. A healthy CSM count is a sign that those training camps are working. A persistently low count is a sign they are not.

Common Variable Immunodeficiency

The strongest evidence for this marker comes from CVID (common variable immunodeficiency), a condition where the body cannot make enough antibodies. Severe deficiency of CSM cells, defined as below 0.4% of B cells, was found in a substantial proportion of CVID patients in the original classification study, while healthy controls generally had higher levels.

Within CVID, low CSM levels track with poor IgG production in the lab, splenomegaly (an enlarged spleen), autoimmune cytopenias (where the immune system attacks blood cells), granulomatous disease, and altered dendritic cell patterns. Patients with low CSM also tend to have more severe hypogammaglobulinemia and bronchiectasis, a form of lung scarring that follows repeated infections.

Selective IgA Deficiency and Suspected Antibody Disorders

In selective IgA deficiency, CSM cells and plasmablasts are reduced, though less severely than in CVID. In a longitudinal study of 305 people with suspected immune disorders, persistently low CSM proportions tightly tracked with combined low IgA and low IgG, pointing to germinal center failure as the underlying problem.

This matters because it means a low CSM is not just a number on a flow cytometry report. It often signals that the part of your immune system responsible for making lasting, class-switched antibodies is not functioning, and that pattern explains why your IgG or IgA levels are low.

Infection Risk After Transplant

In a prospective study of 46 heart transplant recipients, people with higher baseline CSM levels (above roughly 14% of CD27+ B cells) had a substantially lower risk of severe infection in the first year after transplant compared to those at or below that threshold. The protective association held in a multivariable model that included immunoglobulin levels and clinical factors.

In chronic graft-versus-host disease after stem cell transplant, CSM cells are markedly decreased and accompany low IgG and high rates of severe infection, a picture that resembles functional asplenia (when the spleen is no longer doing its immune job).

Autoimmune Disease and Cancer

In rheumatoid arthritis, CSM cells persist in lymph nodes after rituximab treatment and may help sustain disease activity. In melanoma treated with immune checkpoint blockade, CSM cells are enriched in the tumors of people who respond, suggesting they help drive effective anti-tumor immunity. These findings are interesting context, but they are not the reason most people order this test.

Reconciling Apparent Contradictions

Higher CSM is generally good news for infection defense, but their persistence in inflamed lymph nodes in rheumatoid arthritis and their expansion inside some tumors shows that this is a phenotype indicator, not a simple good number, bad number marker. The same cell type can support healthy antibody responses in one tissue and contribute to autoimmune or anti-tumor activity in another. For someone using this test to evaluate their own antibody-producing capacity, what matters is whether circulating CSM levels are present in adequate numbers, not whether the cell type itself is universally beneficial.

Reference Ranges

This is a research-tier marker without universally standardized clinical cutpoints, and ranges depend on the lab's flow cytometry method and the population studied. The thresholds below come from CVID classification work and longitudinal studies of suspected immune disorders. They are useful orientation, not absolute targets, and your lab may report them differently.

Source: Warnatz et al., Blood 2002 (CVID classification); Knight et al., Cytometry Part B 2025 (longitudinal monitoring). Compare your results within the same lab over time for the most meaningful trend.

Tracking Your Trend

A single CSM measurement gives you a snapshot. The longitudinal study of 305 people with suspected immune disorders showed that persistently low CSM proportions, not isolated low readings, were the pattern that tracked with low IgA and IgG and pointed to germinal center failure. This is why repeating the measurement matters more than reacting to one number.

A reasonable approach: get a baseline, retest in 3 to 6 months if you are investigating recurrent infections or making changes, then at least annually thereafter. If your level is borderline or you are on an immune-modifying medication, more frequent testing helps you see the trajectory before it crosses a clinically meaningful threshold.

What to Do With an Abnormal Result

A persistently low CSM result is not a diagnosis on its own. It is a signal worth investigating alongside total IgG, IgA, and IgM levels, vaccine response testing (your antibody response to tetanus or pneumococcal vaccines), and a full B-cell subset panel. If your CSM is low and your IgG or IgA is also low, the combination is what most often points toward a primary antibody deficiency such as CVID or selective IgA deficiency.

This is the point at which involving a clinical immunologist makes sense. They can evaluate whether the pattern fits a defined immunodeficiency, whether you need immunoglobulin replacement therapy, and whether further workup such as genetic testing is warranted. If your CSM is low but your immunoglobulins are normal and you are healthy, the finding is harder to interpret and serial tracking becomes the most useful next step.

When Results Can Be Misleading

• Recent or ongoing immune-modifying therapy: rituximab depletes B cells broadly and produces persistent reductions in CD27+ memory cells in blood for months. Tocilizumab and TNF inhibitors remodel memory B-cell compartments. Fingolimod, dimethyl fumarate, and interferon-beta reduce memory fractions and increase naive fractions. Results during these therapies reflect the drug effect, not your underlying capacity.
• Recent chemotherapy: cytotoxic chemotherapy reduces CD27 expression on antigen-specific B cells and impairs memory maturation. Testing during or shortly after a chemotherapy cycle can underestimate your baseline.
• Acute or recent viral infection: after COVID-19, memory B cell subsets can stay decreased compared to controls for weeks to months post-infection. Testing soon after a major infection can produce a temporary picture that does not reflect your steady state.
• Lab and assay variation: flow cytometry panels and gating strategies vary between labs, which is why comparing results within the same lab over time is more reliable than comparing absolute numbers across different facilities.